Screening for Peripheral Artery Disease Using the Ankle-Brachial Index
Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

Janelle M. Guirguis-Blake, MD; Corinne V. Evans, MPP; Nadia Redmond, MSPH; Jennifer S. Lin, MD, MCR

IMPORTANCE Peripheral artery disease (PAD) is associated with a high risk for cardiovascular events and poor ambulatory function, even in the absence of symptoms. Screening for PAD with the ankle-brachial index (ABI) may identify patients in need of treatment to improve health outcomes.

OBJECTIVE To systematically review evidence for the US Preventive Services Task Force on PAD screening with the ABI, the diagnostic accuracy of the test, and the benefits and harms of treatment of screen-detected PAD.


STUDY SELECTION Studies of unselected or generally asymptomatic adults with no known cardiovascular disease.

DATA EXTRACTION AND SYNTHESIS Independent critical appraisal and data abstraction by 2 reviewers.

MAIN OUTCOMES AND MEASURES Cardiovascular morbidity; PAD morbidity; mortality; health-related quality of life; diagnostic accuracy; and serious adverse events.

RESULTS Five studies (N = 5864 participants) were included that examined the indirect evidence for the benefits and harms of screening and treatment of screen-detected PAD. No population-based screening trials evaluated the direct benefits or harms of PAD screening with the ABI alone. A single diagnostic accuracy study of the ABI compared with magnetic resonance angiography gold-standard imaging (n = 306) found low sensitivity (7%-34%) and high specificity (96%-100%) in a screening population. Two adequately powered trials (n = 4626) in asymptomatic populations with and without diabetes with a variably defined low ABI (≤0.95 or ≤0.99) showed no statistically significant effect of aspirin (100 mg daily) for composite CVD outcomes (adjusted hazard ratio [HR], 1.00 [95% CI, 0.81-1.23] and HR, 0.98 [95% CI, 0.76-1.26]). One trial (n = 3350) demonstrated no statistically significant increase in major bleeding events with the use of aspirin (adjusted HR, 1.71 [95% CI, 0.99-2.97]) and no statistically significant increase in major gastrointestinal bleeding (relative risk, 1.13 [95% CI, 0.44-2.91]). Two exercise trials (n = 932) in screen-relevant populations reported no differences in quality of life, Walking Impairment Questionnaire walking distance, or symptoms at 12 and 52 weeks; no harms were reported.

CONCLUSIONS AND RELEVANCE There was no direct evidence and limited indirect evidence on the benefits of PAD screening with the ABI in unselected or asymptomatic populations. Available studies suggest low sensitivity and lack of beneficial effect on health outcomes, but these studies have important limitations.


Editorial page 143
Related article page 177 and JAMA Patient Page page 212
Supplemental content

Author Affiliations: Department of Family Medicine, University of Washington, Tacoma (Guirguis-Blake); Kaiser Permanente Research Affiliates Evidence-based Practice Center, Center for Health Research, Kaiser Permanente, Portland, Oregon (Guirguis-Blake, Evans, Redmond, Lin).

Corresponding Author: Janelle M. Guirguis-Blake, MD, Kaiser Permanente Research Affiliates Evidence-based Practice Center, Department of Family Medicine, University of Washington, 521 Martin Luther King Jr Way, Tacoma, WA 98405 (jguirgui@u.washington.edu).

© 2018 American Medical Association. All rights reserved.
Peripheral artery disease (PAD) is associated with a high risk for cardiovascular (CVD) events and poor ambulatory function. Because it is often asymptomatic, PAD is underdiagnosed, and as a result, those who have it may not receive appropriate treatment. Early detection and treatment of PAD could improve health outcomes by initiating risk factor modification in people with undiagnosed atherosclerosis to reduce CVD outcomes, and interventions to slow functional decline of the lower extremity.

The most commonly used screening test for PAD is the ankle-brachial index (ABI), which is the ratio of the ankle and brachial systolic blood pressures. While the ABI is recommended in patients with symptoms, less is known about the benefits and harms of its use for early detection and treatment in asymptomatic patients. In 2013, the US Preventive Services Task Force (USPSTF) concluded that evidence was insufficient to assess the balance of benefits and harms of using the ABI to screen for PAD and assess CVD risk in asymptomatic adults.

The aim of this systematic review was to update the evidence on the benefits and harms of screening for PAD using the ABI, including the diagnostic accuracy of the test, and the benefits and harms of treating screen-detected patients, to inform the USPSTF in updating its recommendations.

Methods

Scope of Review
This review addressed 5 key questions (KQs), shown in Figure 1. Additional methodological details, including a detailed description of study selection and a list of excluded studies, and additional tabular outcome data for exercise trials, are available in the full evidence report at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/peripheral-artery-disease-in-adults-screening-with-the-ankle-brachial-index.

Data Sources and Searches
This review is an update of the screening, diagnostic accuracy, treatment, and harms KQs of a prior systematic review commissioned by the USPSTF. All previously included studies were reviewed for potential inclusion, and Ovid MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials were searched to identify new literature published between January 2012 and May 2, 2017 (eMethods in the Supplement). Additionally, reference lists from recent systematic reviews were examined, and ClinicalTrials.gov was searched to identify relevant ongoing trials. Since May 2, 2017, ongoing surveillance through article alerts and targeted searches of journals with a high impact factor and journals relevant to the topic were conducted to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and therefore the related USPSTF recommendation. The last surveillance was conducted on February 7, 2018, and identified 1 screening trial that was formally evaluated for inclusion but that did not meet the review criteria.

Study Selection
Two reviewers independently reviewed 4194 unique citations and 105 full-text articles against a priori inclusion criteria (Figure 2; eTable 1 in the Supplement). This review focused on screen-detected or generally asymptomatic adults without known CVD; therefore, studies whose participants primarily had the classic PAD symptom of intermittent claudication were excluded. This review allowed studies with participants reporting atypical symptoms with higher baseline values for ABI and lower extremity function who might also be representative of a screen-detected group. For each KQ, analyses were specified a priori for the following population characteristics: age, sex, race/ethnicity, smoking history, and presence of diabetes or hypertension. These are presented where available but were rarely reported. The credibility of subpopulation analyses was evaluated based on the timing of planned analyses, interaction testing for heterogeneity of treatment effect, baseline comparability, and control for confounders.

The primary outcomes of interest were cardiovascular morbidity, defined as myocardial infarction (MI) and cerebrovascular accident (CVA); PAD morbidity, which included ambulation impairment (eg, as measured by the Walking Impairment Questionnaire [WIQ], which is measured on a scale of 0-100), or amputation; mortality; health-related quality of life; diagnostic accuracy of the resting ABI (sensitivity, specificity, positive predictive value, negative predictive value); adverse outcomes related to the ABI test; and serious adverse events related to treatment. In studies reporting WIQ outcomes, proportions of the population with symptoms at baseline and follow-up were abstracted and reported.

For treatment KQs (KQ4 and KQ5), pharmacologic or lifestyle interventions aimed at reducing CVD risk were included. New in this update were exercise and physical therapy interventions aimed at improving lower limb function.

For KQ1, randomized clinical trials (RCTs), nonrandomized controlled intervention studies, and systematic reviews that compared screening using the resting ABI with no screening and reported a primary outcome were eligible. For KQ2, prospectively conducted diagnostic accuracy studies and well-conducted systematic reviews of diagnostic accuracy were eligible. Case-control studies were excluded because selection of participants in this study design has been shown to overestimate sensitivity and result in spectrum bias. For KQ2, diagnostic accuracy studies had to compare the resting ABI with a reference standard (ie, any diagnostic test that could image the degree of atherosclerosis or degree of impaired blood flow). For KQ4, any trial or systematic review with at least 12 weeks of follow-up that compared treatment of PAD with no treatment, with placebo treatment, or with delayed treatment was eligible. For evaluation of harms (KQ3 and KQ5), trials, cohort studies, and case-control studies were included; case series or case reports were excluded.

Data Extraction and Quality Assessment
Included studies were critically appraised by 2 independent reviewers using predefined criteria, with disagreements resolved by a third reviewer (eTable 2 in the Supplement). Articles were rated as good, fair, or poor quality. In general, a good-quality study met all criteria. A fair-quality study did not meet, or it was unclear whether it met, at least 1 criterion but had no known important limitations that could invalidate its results. A poor-quality study had a single fatal flaw or multiple important limitations.
limitations. Poor-quality studies were excluded because of substantial concerns about the validity of results for the KQ being addressed. One reviewer abstracted descriptive and outcome data from each study into standardized evidence tables; a second checked for accuracy and completeness.

Data Synthesis and Analysis
Data were synthesized separately for each KQ. The number of contributing studies was not sufficient for quantitative pooling for any KQ, so data are summarized narratively and in tables. For diagnostic accuracy studies (KQ2), false-positive rates (positive test given the absence of the disease [1 – specificity]) and false-negative rates (negative test result given the presence of the disease [1 – sensitivity]) were calculated; confidence intervals were calculated using the Agresti-Coull method.27 For treatment trials (KQ4), standard deviations for continuous outcomes were converted to 95% CIs. For dichotomous outcomes, measures of association and between-group P values were calculated where not reported with 1- and 2-sample tests of proportions at the 5% significance level (2-sided test). Stata version 13.1 (StataCorp) was used for all quantitative analyses. Calculation methods are described further in the full report.

Results
Five studies (N = 5864) met the inclusion criteria for this review (Figure 2). No direct evidence for PAD screening was identified for KQ1. One study included in the previous USPSTF systematic review evaluated the diagnostic accuracy of the ABI for KQ2 and KQ3.28 Four trials addressed treatment benefits and harms in screen-relevant populations for KQ4 and KQ5.29-32

Benefits of Screening
Key Question 1. Is screening for PAD in generally asymptomatic adults with the ABI effective in reducing CVD or PAD morbidity (eg, impaired ambulation or amputation) or mortality?

No population-based randomized trials of ABI screening alone were identified. Three multicomponent screening trials are in progress, 2 in Denmark (ISRCTN12157806, NCT00662480)
In total, the current review included 6 articles (5 studies); studies may appear in more than 1 key question (KQ). Reasons for exclusion: Aim: study aim not relevant. Setting: study not conducted in a country relevant to US practice or was conducted or recruited from hospital or specialty settings such as vascular clinics or laboratories that typically represented populations selected for known or highly suspected peripheral artery disease (PAD). Population: study not conducted in unselected or community-dwelling generally asymptomatic adults (KQ1, KQ2, and KQ3) or study was not conducted in screen-detected or highly suspected peripheral artery disease (PAD). Setting: study not conducted in a country relevant to US practice or was conducted or recruited from hospital or specialty settings such as vascular clinics or laboratories that typically represented populations selected for known or highly suspected peripheral artery disease (PAD). Population: study not conducted in unselected or community-dwelling generally asymptomatic adults (KQ4 and KQ5). Outcomes: study did not report required outcomes. Intervention: intervention was out of scope. Design: study did not use an included design. Did not use reference standard: for KQ2 and KQ3, the ABI was not compared with an eligible reference standard. Quality: study was poor quality.

Accuracy of Screening

Key Question 2. What is the diagnostic accuracy of the ABI as a screening test for PAD in generally asymptomatic adults?

Evidence for the diagnostic accuracy of the ABI as a screening test for PAD in asymptomatic adults is limited to 1 older fair-quality study published in 2008 that showed low sensitivity and high specificity. That study of 306 older adults in Sweden used whole-body magnetic resonance angiography (MRA) as the reference standard to confirm the presence of PAD. The study recruited adults aged 70 years at study entry from a random subset of the population-based Prospective Investigation of the Vasculature in Uppsala Seniors cohort study (n = 1016). Forty-seven percent of participants were women, 6.9% had experienced a previous MI, 3.9% had experienced a previous CVA, and 10.6% had diabetes. About 8% were current smokers.

The ABI was calculated for each leg by dividing the manual sphygmomanometer readings of posterior tibial artery systolic pressure by the mean of 3 brachial artery systolic pressures. A low ABI was defined as less than 0.9, and accuracy was calculated based on the whole-body MRA gold standard, with PAD diagnosis defined as 50% or greater stenosis.

The prevalence of an ABI less than 0.9 was 4.5% in the right leg and 4.2% in the left leg (Table 1). The prevalence of MRA-confirmed PAD defined as 50% or greater stenosis was 19.0% in the right leg and 23.0% in the left leg.

Sensitivity was 20% (95% CI, 10%-34%) in the right leg and 15% (95% CI, 7%-27%) in the left leg. Specificity was 99% (95% CI, 96%-100%) in both legs. Positive predictive value was 83% (95% CI, 51%-97%) in the right leg and 82% (95% CI, 48%-97%) in the left leg. Negative predictive value was 84% (95% CI, 79%-88%) in the right leg and 80% (95% CI, 74%-84%) in the left leg.

Harms of Screening

Key Question 3. What are the harms of screening for PAD with the ABI?

Evidence for the harms of screening for PAD with the ABI was limited to false-positive and false-negative rates in the aforementioned diagnostic accuracy study (Table 1). The false-positive rate was 0.9% (95% CI, 0.0%-3.5%) in the right leg and 1.0% (95% CI, 0.0%-3.7%) in the left leg; the false-negative rate was 80.4% (95% CI, 67.4%-89.2%) in the right leg and 85.2% (95% CI,
Benefits of Treatment

Key Question 4. Does treatment of screen-detected or generally asymptomatic adults with PAD or an abnormal ABI lead to improved patient health outcomes?

The evidence for treatment of screen-detected or generally asymptomatic adults with an abnormal ABI to improve health outcomes consists of 2 large RCTs of aspirin and 2 RCTs of exercise.

Aspirin

Two good-quality trials (n = 4626), both conducted in Scotland, examined the effectiveness of aspirin in populations with a low ABI. The Aspirin for Asymptomatic Atherosclerosis (AAA) trial (n = 3350) was a placebo-controlled RCT, and the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial (n = 1276) was a factorial-designed RCT of aspirin and antioxidant tablet vs placebo. Authors reported no evidence of an interaction between aspirin and antioxidants, so results were analyzed for the group taking aspirin compared with the group not taking aspirin.

Both trials showed no difference between the aspirin and control groups in trial-defined composite cardiovascular outcomes, fatal CVD events, or all-cause mortality (Table 2). The examination of individual CVD outcomes such as MI and CVA likewise showed no statistically significant difference between the aspirin and control groups (eTable 3 in the Supplement). Subgroup credibility ratings did not support a differential treatment effect by age or sex. Within-trial comparisons revealed overlapping confidence intervals, and POPADAD—the single trial with heterogeneity testing for CVD outcomes by age and sex—reported nonstatistically significant interaction testing (eTable 4 and eTable 5 in the Supplement).

Exercise

Two trials examined the effectiveness of exercise in populations with low ABI: a good-quality Australian trial by Fowler et al (n = 882) and a small, fair-quality US pilot study by Collins et al (n = 50). The first trial recruited participants from the population-based Western Australian abdominal aortic aneurysm screening trial, while the US pilot RCT included participants with a low ABI, defined as less than 0.9, and no intermittent claudication who were referred to a Veterans Administration vascular...
Abbreviations: AAA, Aspirin for Asymptomatic Atherosclerosis trial; Aspirin for Asymptomatic Atherosclerosis trial; WIQ, Walking Impairment Questionnaire; ABI, ankle-brachial index; POPADAD, Prevention of Organism Progression in Atherosclerosis and its Determinants in Diabetes trial.

Table 2. Composite and Mortality Outcomes for Aspirin in Participants With Low Ankle-Brachial Index (Key Question 4)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Trial</th>
<th>No. With the Event/Total No. (%)</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary composite CVD outcomea</td>
<td>AAAb</td>
<td>181/1675 (10.8)</td>
<td>1.00 (0.81-1.23)e</td>
</tr>
<tr>
<td></td>
<td>POPADADc</td>
<td>116/638 (18.2)</td>
<td>0.98 (0.76-1.26)</td>
</tr>
<tr>
<td>Composite fatal coronary events</td>
<td>AAAb</td>
<td>35/1675 (2.1)*</td>
<td>1.17 (0.72-1.89)</td>
</tr>
<tr>
<td>+ CVA + CVD death</td>
<td>POPADADc</td>
<td>63/638 (9.7)</td>
<td>1.17 (0.79-1.93)</td>
</tr>
<tr>
<td>Composite nonfatal MI + CVA</td>
<td>AAAb</td>
<td>99/1675 (5.9)*</td>
<td>0.93 (0.72-1.22)</td>
</tr>
<tr>
<td></td>
<td>POPADADc</td>
<td>84 (13.2)*</td>
<td>0.87 (0.66-1.14)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>AAAb</td>
<td>136/1675 (8.2)</td>
<td>0.95 (0.71-1.24)</td>
</tr>
<tr>
<td></td>
<td>POPADADc</td>
<td>135/638 (21.3)</td>
<td>0.95 (0.71-1.24)</td>
</tr>
</tbody>
</table>

| Abbreviations: AAA, Aspirin for Asymptomatic Atherosclerosis trial; CVA, cerebrovascular accident; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; POPADAD, Prevention of Progression of Arterial Disease and Diabetes. |

a Defined in the AAA trial as initial fatal or nonfatal coronary event or CVA or revascularization; defined in the POPADAD trial as death from coronary heart disease or CVA, nonfatal MI or CVA, or above-ankle amputation for critical limb ischemia.

Laboratory. Primary outcomes were the change from baseline to follow-up at 1231 and 52 weeks32 in walking ability; this was defined in the trial by Fowler et al32 as the ability to walk 91.4 to 365.8 m before onset of intermittent claudication and in the trial by Collins et al31 as the WIQ walking distance score. Because the trial by Collins et al was designed as a small, short-term feasibility study, it was not powered for its primary outcome.

Compared with the populations in the aspirin trials, participants in the exercise trials were more frequently men, older, more symptomatic, and had lower ABI. Both trials were exclusively or almost exclusively conducted among men. Mean age was 73.1 years in the trial by Fowler et al and 69.1 years in the trial by Collins et al. Because the trial by Fowler et al recruited participants who screened positive for PAD via either the ABI or the Edinburgh Claudication Questionnaire, about 44% of the population had intermittent claudication; atypical symptoms were present in about 9% of the population, and the remainder were asymptomatic. Fifty-six percent of participants in the trial by Collins et al were asymptomatic for PAD, and the remaining 44% had atypical symptoms. Mean ABI was 0.79 in the trial by Fowler et al and 0.74 in the trial by Collins et al.

The interventions in the 2 trials were somewhat heterogeneous with respect to format and intensity; each trial included lifestyle messages in addition to exercise. Intervention details are provided in eTable 6 in the Supplement. The intervention in the trial by Fowler et al included a smoking cessation intervention and physical therapy referral. The 52-week intervention began with an individual face-to-face session including explanation of the PAD screening test results and provision of an educational packet about PAD, a brochure about the community physical therapy service, smoking cessation information if applicable, and a copy of the letter sent to the patient’s general practitioner. The community physical therapy service goal was to increase physical activity and included weekly 45-minute supervised sessions for 49 sessions or an individually designed, home-based physical activity program. In addition, all men were advised to walk for 30 minutes or more each day. In the control group, nurses disclosed results of diminished flow to the lower extremities but told participants that “there is presently no evidence to suggest you do anything about it at this time.”

The intervention in the trial by Collins et al included 2 components delivered individually by a nurse: risk factor modification and counseling to improve physical activity. The 12-week intervention started with a face-to-face session followed by 5 telephone visits, each lasting less than 30 minutes. The control group was advised to continue routine care with primary care physicians. Adherence to the physical activity component differed widely between the 2 trials: it was relatively low in the longer trial by Fowler et al (16.5% at 1 year of follow-up) and high in the 12-week trial by Collins et al related to the physical activity recommendation of 30 minutes 3 times per week (40% at baseline and 82% by the final telephone call).

The variability of outcome measures reported in the 2 trials precludes definitive conclusions, but generally, evidence suggests that exercise-based treatment of screen-detected PAD may have limited effectiveness. Neither trial showed statistically significant between-group differences in self-reported quality of life, as measured by the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), used in the trial by Collins et al, or the Rosser Health-related Quality of Life instrument, used in the trial by Fowler et al. Only the trial by Collins et al reported eligible ambulation impairment outcomes, showing no difference in the primary outcome of mean walking distance score on the WIQ or walking speed. However, a statistically significant larger improvement was found for the intervention group for the stair-climbing component of the WIQ compared with the control group (mean difference, 15.1 [95% CI, 2.4 to 32.6]; P = 0.02). Neither trial showed statistically significant between-group differences for the proportion of participants experiencing symptoms between baseline and follow-up. However, in the trial by Fowler et al, the proportion of participants experiencing atypical symptoms and intermittent claudication decreased in both the intervention and the control groups. Symptom patterns in the trial by Collins et al were more inconsistent, possibly because of a very small sample.
Harms of Treatment

Key Question 5. What are the harms of treatment of screen-detected or generally asymptomatic adults with PAD or an abnormal ABI?

Evidence for the harms of treatment are limited to the 2 trials of aspirin and suggest that aspirin may be associated with increased major bleeding, although rare events and wide confidence intervals preclude definitive conclusions from these studies alone. Both the AAA and the POPADAD trials reported bleeding harms associated with use of 100 mg of aspirin daily. Major gastrointestinal bleeding requiring hospital admission was similar in the aspirin and control groups (0.5% vs 0.5%; relative risk [RR], 1.13 [95% CI, 0.44-2.91]). Major hemorrhage (defined as nonfatal or fatal hemorrhagic CVA, fatal or nonfatal subarachnoid or subdural hemorrhage, gastrointestinal bleeding requiring admission, and other bleeding requiring hospital admission) in the AAA trial was higher in the aspirin group but did not reach statistical significance (2.0% vs 1.2%; HR, 1.71 [95% CI, 0.99-2.97]). Five hemorrhagic CVAs occurred in the aspirin group and 4 in the control group; confidence intervals were wide, because of the rare event rate (0.3% vs 0.2%; RR, 1.25 [95% CI, 0.34-4.65]). The POPADAD trial reported a nonsignificant reduction in fatal hemorrhagic CVA in the aspirin group, but again, confidence intervals were wide because of rare events (2 events [0.3%] vs 3 events [0.5%]; RR, 0.67 [95% CI, 0.11-3.98]).

Discussion

An overall summary of the evidence is presented in Table 3. No population-based screening trials address the effectiveness of ABI screening for PAD as a single intervention to reduce PAD- or CVD-related morbidity or mortality. The indirect chain of evidence linking screening with the ABI in generally asymptomatic adults to improved health outcomes is limited (Figure 1). A single diagnostic accuracy study demonstrates that the ABI has poor sensitivity for detecting PAD in unselected populations; that same study was included in the previous review for the USPSTF. Evidence for treatment benefit consists of 2 trials of aspirin and 2 trials of exercise; 1 of the aspirin trials29 and both exercise systematic reviews in largely symptomatic populations. The literature centered on symptomatic populations has concluded that exercise programs are associated with improved maximum walking distance and time, pain-free walking distance, 6-minute walk, WIQ scores, and quality of life.9,12-14 Expecting unselected populations to achieve improvements in ambulation may not be reasonable if they are not reporting symptoms; however, if patients are unaware of symptoms because they have limited their activity levels, treatment could potentially improve ambulation and quality of life. Several observational studies of screen-detected or asymptomatic populations do show that those with a low ABI have statistically significant worse measures of function than those with a normal ABI, including 6-minute walk distance, 4-m walking velocity, 400-m walk time, SF-36 physical functioning subscale scores, and WIQ distance and speed scores.41-46 Two exercise-based intervention trials in patients with PAD or a low ABI showed improved lower-extremity functional outcomes but were not included in this review because the baseline ABIs and WIQ distance and speed scores reflect a more severe functional impairment and disease severity than would be expected in an unselected, screen-detected primary care population.47,48 Replication of these findings in screened populations is needed.

Other systematic reviews of antiplatelet therapy have similarly reported no overall reduction in CVD events with aspirin compared with control in populations with low ABI.9,15,16 Findings of bleeding risk associated with aspirin use should be considered in the context of the broader literature about aspirin use for CVD primary prevention.9 The present review did not identify any other pharmacologic trials in screen-detected PAD populations reporting patient health outcomes. Observational studies suggest both functional and mortality benefits of statins.9,50-53 An RCT of statin therapy in individuals with an abnormal ABI may be of uncertain value because many of these individuals may qualify for statin therapy based on 10-year risk alone—data from a 2008 large, individual participant data meta-analysis suggest that 95% of men and 41% of women with an ABI of 0.9 or less would already be above a 10% Framingham Risk Score 10-year risk threshold.1
Table 3. Summary of Evidence by Key Question

| Total No. of Studies and Design, No. of Participants Randomized | No. of Trials (No. of Participants Analyzed) | Outcome | Summary of Findings by Outcome | Consistency and Precision | Reporting Bias | Study Quality | Body of Evidence Limitations | Applicability |
|---|---|---|---|---|---|---|---|---|---|
| KQ1: Effectiveness of Screening | 0 studies | Morbidity or mortality | 0 | NA | NA | NA | NA | NA | NA |
| KQ2: Diagnostic Accuracy of Screening | 1 Prospective diagnostic accuracy study, n = 307 (0/1 trials identified in update) | Sensitivity, specificity, PPV, NPV | 1 (n = 306)* | ABI has low sensitivity (7%-34%) and high specificity (96%-100%) vs MRA gold standard imaging | Consistency NA (single study) | Imprecise | Fair | Single study, not clear if MRA interpreters were blinded to ABI results; harms (aside from false positives and false negatives) not reported other than single vasovagal episode | Screening population of older adults (70 y) in Sweden. The low sensitivity reported in this single study is well below the sensitivities reported in symptomatic populations |
| KQ3: Harms of Screening | 1 Prospective diagnostic accuracy study, n = 307 (0/1 trials identified in update) | Harms | 1 (n = 306)* | ABI has high false-negative rate (>80%) reflecting low sensitivity in screening for PAD | Consistency NA (single study) | Imprecise | Fair | Single study, not clear if MRA interpreters were blinded to ABI results; harms (aside from false positives and false negatives) not reported other than single vasovagal episode | Screening population of older adults (70 y) in Sweden. The low sensitivity reported in this single study is well below the sensitivities reported in symptomatic populations |
| KQ4: Benefits of Treatment | Aspirin 2 RCTs, n = 4626 (1/2 trials identified in update) | CVD composite, ACM, individual CVD outcomes | 2 (n = 4626) | Aspirin (100 mg daily) showed no effect on CVD composite events in the 2 trials: adjusted HR, 1.00 (95% CI, 0.81-1.23) and HR, 0.98 (95% CI, 0.76-1.26) | Reasonably consistent | Imprecise | Good | Studies designed to detect differences in CVD composites but not individual CVD outcomes | Two Scottish trials in asymptomatic patients with low ABI defined as ≤0.95 and ≤0.99 (thresholds not typically used to define abnormal ABI in clinical practice). One trial exclusively in patients with diabetes. Populations at intermediate to high CVD risk |
| | Exercise 2 RCTs, n = 932 (2/2 trials identified in update) | Quality of Life | 2 (n = 745) | No difference in quality of life changes from baseline (as measured by MOS SF-36 and Rosser HRQOL questionnaire) | Reasonably consistent | Imprecise | 1 Good, 1 fair | One feasibility trial in almost exclusively men was short (12 weeks) and underpowered (n = 852) powered to detect walking ability before onset of symptoms | Unclear whether population representative of screen-detected population; participants almost 100% men |
| | | WIQ | 1 (n = 48) | No difference in WIQ score change from baseline for distance or speed components; statistically significant improvement in stair climbing component in intervention group vs control group | NA | Not detected | Fair | |
| | | Proportion of participants with symptoms | 2 (n = 722) | No change in proportion of participants who developed intermittent claudication or atypical symptoms | Reasonably consistent | Imprecise | 1 Good, 1 fair | |

(continued)
Table 3. Summary of Evidence by Key Question (continued)

<table>
<thead>
<tr>
<th>Total No. of Studies and Design, No. of Participants Randomized</th>
<th>Outcome</th>
<th>No. of Trials (No. of Participants Analyzed)</th>
<th>Summary of Findings by Outcome</th>
<th>Consistency and Precision</th>
<th>Reporting Bias</th>
<th>Study Quality</th>
<th>Body of Evidence Limitations</th>
<th>Applicability</th>
</tr>
</thead>
<tbody>
<tr>
<td>KQ4a: Benefits of Treatment by Subpopulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>CVD composite, individual CVD outcomes, fatal CVD events, ACM</td>
<td>2 (n = 4626)</td>
<td>No compelling evidence to support differential treatment effect by age, sex, or diabetes status within-trial comparisons revealed overlapping CIs; the single trial (POPADAD) reporting heterogeneity testing for CVD outcomes by age and sex reported nonstatistically significant interaction testing results exclusively in participants with diabetes (POPADAD) showing outcomes similar to those almost exclusively without diabetes (AAA)</td>
<td>Inconsistent (age) Reasonably consistent (sex)</td>
<td>Not detected</td>
<td>Good</td>
<td>Only 1 trial performed interaction testing by age and sex; unclear if a priori planned analysis other trial prespecified subgroup analysis but did not perform interaction testing no available data for within-group comparisons by diabetes status CIs wide and overlapping across subgroups analyzed</td>
<td>Both Scottish trials in asymptomatic patients with low ABI defined as ≤0.95 and ≤0.99 (thresholds not typically used to define abnormal ABI in clinical practice) one trial exclusively in patients with diabetes populations at intermediate to high CVD risk</td>
</tr>
<tr>
<td>Exercise</td>
<td>NA</td>
<td>NA</td>
<td>No exercise trials examine the differential treatment effect by subpopulation</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>KQ5: Harms of Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>Major GI bleeding requiring admission</td>
<td>1 (n = 3350)</td>
<td>Major GI bleeding requiring hospital admission was similar in 1 reporting trial (AAA) of aspirin (100 mg, enteric coated) at 8.2 y of follow-up; 0.5% vs 0.5%; RR, 1.13 (95% CI, 0.44-2.91) Limitation evidence from this trial demonstrates a higher risk for major bleeding events with the use of aspirin but was not statistically significant two trials reported conflicting results on total or fatal hemorrhagic CVA risk with wide CIs attributable to rare event rate</td>
<td>Consistency NA (single study) Imprecise</td>
<td>Not detected</td>
<td>Good</td>
<td>Rare events, wide CIs</td>
<td>Asymptomatic patients with low ABI defined as ≤0.95 with intermediate CVD risk</td>
</tr>
<tr>
<td></td>
<td>Major hemorrhage (defined as nonfatal or fatal hemorrhagic CVA, fatal or nonfatal subarachnoid/ subdural hemorrhage, GI bleeding requiring admission, and other bleeding requiring hospital admission)</td>
<td>1 (n = 3350)</td>
<td>Major hemorrhage did not reach statistical significance but was slightly higher in the aspirin group: 2.0% vs 1.2%; HR, 1.71 (95% CI, 0.99-2.97)</td>
<td>Consistency NA (single study) Imprecise</td>
<td>Not detected</td>
<td>Good</td>
<td>Single trial, relatively rare event with wide CIs</td>
<td></td>
</tr>
<tr>
<td>Hemorrhagic CVA</td>
<td>2 (n = 4626)</td>
<td>Nonsignificant higher risk for total hemorrhagic CVA with aspirin in AAA (0.3% vs 0.2%; RR, 1.25 [95% CI, 0.34-4.65]; and a lower risk for fatal hemorrhagic CVA in POPADAD (0.3% vs 0.5%; RR, 0.67 [95% CI, 0.11-3.98]), but CIs were wide because of rare events</td>
<td>Inconsistent, Imprecise</td>
<td>Not detected</td>
<td>Good</td>
<td>Somewhat conflicting results when comparing total and fatal hemorrhagic CVA across 2 trials that recruited different populations (with and without diabetes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>0 studies</td>
<td>No trials reporting harms</td>
<td>NA</td>
<td>NA</td>
<td>Good</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AAA, Aspirin for Asymptomatic Atherosclerosis Trial; ABI, ankle-brachial index; ACM, all-cause mortality; CVA, cerebrovascular accident; CVD, cardiovascular disease; EPC, Evidence-based Practice Center; GI, gastrointestinal; HR, hazard ratio; HRQL, health-related quality of life; KQ, key question; MI, myocardial infarction; MOS SF-36, Medical Outcomes Study 36-Item Short Form Health Survey; MRA, magnetic resonance angiography; NA, not applicable; PAD, peripheral artery disease; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; RCT, randomized clinical trial; RR, relative risk; WIQ, Walking Impairment Questionnaire. a Of 307 participants randomized, only 306 were analyzed (1 participant did not complete gold standard test).
Some organizations recommend screening for PAD with the ABI in populations above certain ages or with various risk factors (Table 4). The rationale is that high-prevalence populations, such as those at older age, with diabetes, and who smoke cigarettes, can be easily identified based on established risk factors for PAD; that the ABI is relatively accurate based on studies in symptomatic patients; and that cardiovascular risk factor modification is appropriate because CVD morbidity and mortality are high in adults with PAD, regardless of symptoms. Conversely, even when higher-prevalence populations with high CVD risk are identified for screening, the missing link in the indirect evidence chain remains the effectiveness of screening in identifying individuals who are not already candidates for lifestyle and pharmacologic treatment based on their global CVD risk.

Three population-based screening trials are testing the effectiveness of combined multiple vascular screening tests on all-cause mortality, cardiovascular morbidity and mortality, or both at 10 to 15 years of follow-up. However, none of these trials isolates the independent effectiveness of ABI screening. The Viborg Vascular (VIVA) screening trial enrolled 50 156 men aged 65 to 74 years and randomized to screening vs no screening for hypertension, PAD, and abdominal aortic aneurysm; the intervention included subsequent counseling for physical activity, smoking cessation, and a low-fat diet, as well as cholesterol testing with aspirin and statin therapy prescribed to those meeting the screen-detected population in terms of disease severity and in the context of current treatment thresholds for pharmacotherapy based on global CVD risk is uncertain, as nearly all participants would have a 10% or greater 10-year CVD risk based on age and male sex alone and thus would already be candidates for consideration of statins or aspirin. Secondary analyses, including cost-effectiveness analyses to estimate the independent effect of ABI screening, are planned, but it is unlikely that such analyses will definitively demonstrate ABI screening effectiveness given the aforementioned considerations.

Two other large, in-progress multicomponent screening trials (ISRCTN12157806, NCT03228459) using population-based or primary care–based recruitment include the ABI as part of the multicomponent screening intervention and will report primary outcomes of all-cause mortality and CVD events at 10 years of follow-up. As with the VIVA trial, the multicomponent nature of these trials will likely preclude definitive conclusions about the effect of ABI screening alone.

Limitations
This evidence report has several limitations. To be consistent with the scope of the USPSTF, the review excluded symptomatic individuals for both diagnostic accuracy and treatment questions. However, the varied clinical presentation of PAD and the recognition that severity of leg symptoms may not directly correspond to atherosclerotic burden are problematic in identifying a screening-relevant population. The scope of this review did not include diagnostic accuracy of other screening methods or modalities, such as automated oscillometric ABI measurement methods, the post-exercise ABI, which may be relevant in clinically “asymptomatic” populations who self-limit exertion; and the toe-brachial index.

For treatment trials, the narrow population requirement could be considered unnecessarily limiting. However, to develop an indirect chain of evidence in support of screening, it is critical that treatment trials be applicable to a population that reflects the screen-detected population in terms of disease severity and population for which screening is recommended

### Table 4. Recommendations for Screening for PAD With ABI in Individuals Without History or Physical Examination Findings Suggestive of PAD

<table>
<thead>
<tr>
<th>Organization</th>
<th>Age Criteria</th>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>USPSTF 2018</td>
<td>Aged &gt;65 y</td>
<td>Classified as high CVD risk according to ESC guidelines; aged &gt;50 y with family history; known atherosclerotic disease (CAD, any PAD), AAA, CKD, heart failure</td>
</tr>
<tr>
<td>ESC 2017</td>
<td>Aged &gt;65 y</td>
<td>Classified as high CVD risk according to ESC guidelines; aged &gt;50 y with family history; known atherosclerotic disease (CAD, any PAD), AAA, CKD, heart failure</td>
</tr>
<tr>
<td>AHA/ACC 2016</td>
<td>Aged &gt;65 y</td>
<td>Classified as high CVD risk according to ESC guidelines; aged &gt;50 y with family history; known atherosclerotic disease (CAD, any PAD), AAA, CKD, heart failure</td>
</tr>
<tr>
<td>SVS 2015</td>
<td>Aged &gt;65 y</td>
<td>Classified as high CVD risk according to ESC guidelines; aged &gt;50 y with family history; known atherosclerotic disease (CAD, any PAD), AAA, CKD, heart failure</td>
</tr>
<tr>
<td>AAFP 2017</td>
<td>Aged &gt;65 y</td>
<td>Classified as high CVD risk according to ESC guidelines; aged &gt;50 y with family history; known atherosclerotic disease (CAD, any PAD), AAA, CKD, heart failure</td>
</tr>
<tr>
<td>NICE 2012</td>
<td>Aged &gt;65 y</td>
<td>Classified as high CVD risk according to ESC guidelines; aged &gt;50 y with family history; known atherosclerotic disease (CAD, any PAD), AAA, CKD, heart failure</td>
</tr>
<tr>
<td>ACPM 2011</td>
<td>Aged &gt;65 y</td>
<td>Classified as high CVD risk according to ESC guidelines; aged &gt;50 y with family history; known atherosclerotic disease (CAD, any PAD), AAA, CKD, heart failure</td>
</tr>
<tr>
<td>Clinicians should be alert to symptoms in those at increased risk (&gt;50 y, smokers, and those with DM) and evaluate patients with clinical evidence of vascular disease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AAA, abdominal aortic aneurysm; ABI, ankle-brachial index; ACPM, American College of Preventive Medicine; AHA/ACC, American Academy of Family Physicians; AAFP, American Academy of Family Physicians; CAD, coronary artery disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; ESC, European Society of Cardiology; NR, not reported; PAD, peripheral artery disease; SVS, Society for Vascular Surgery; USPSTF, US Preventive Services Task Force.
treatment effectiveness. The prespecified health outcomes required in this review include CVD and PAD morbidity or mortality or quality of life, with the exclusion of intermediate outcomes such as behavior changes, ABI changes, intermediate cardiovascular risk factors, or intermediate measures of lower limb function to include the 6-minute walk test or lower-extremity strength. No treatment trials were excluded from this review on the basis of reporting 6-minute walk outcomes.

ARTICLE INFORMATION
Accepted for Publication: March 19, 2018.
Author Contributions: Dr Guirguis-Blake had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Guirguis-Blake, Evans, Lin.
Acquisition, analysis, or interpretation of data: Guirguis-Blake, Evans, Redmond.
Drafting of the manuscript: Guirguis-Blake, Evans, Lin.
Redmond.
Critical revision of the manuscript for important intellectual content: Guirguis-Blake, Evans, Lin.
Statistical analysis: Guirguis-Blake, Redmond.
Obtained/funding: Lin.
Administrative, technical, or material support: Evans, Redmond.
Supervision: Guirguis-Blake, Evans, Lin.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
Funding/Support: This research was funded under contract HHSAG2902015G00071, Task Order 2, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, under a contract to support the USPSTF.
Role of the Funder/Sponsor: AHRQ had no role in the study design, data collection, data analysis, data interpretation, or manuscript preparation.

Role of the Funder/Sponsor: Investigators worked with USPSTF members and AHRQ staff to develop the scope, analytic framework, and key questions for this review. AHRQ had no role in study design, quality assessment, or supervision. AHRQ staff provided project oversight, reviewed the report to ensure that the analysis met methodological standards, and distributed the draft for peer review. Otherwise, AHRQ had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript findings. The opinions expressed in this document are those of the authors and do not reflect the official position of AHRQ or the US Department of Health and Human Services.

Additional Contributions: We gratefully acknowledge the following individuals for their contributions to this project: Smyth LaI, MLS, Erin Coppola, MPH, and Katherine Essick, BS (Kaiser Permanente Center for Health Research); Selvi Williams, MD, MPH (Oregon Health & Science University); Justin Mills, MD, MPH (Agency for Healthcare Research and Quality [AHRQ]); Elisabeth Kato, MD, MRP (formerly at AHRQ); and current and former members of the US Preventive Services Task Force who contributed to topic deliberations. USPSTF members, peer reviewers, and federal partner reviewers did not receive financial compensation for their contributions.

Additional Information: A draft version of this evidence report underwent external peer review from 3 content experts (Gerry Fowkes, MD, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh; Mary McDermott, MD, Feinberg School of Medicine, Northwestern University; and Joshua Beckman, MD, Division of Cardiovascular Medicine, Vanderbilt University) and 1 federal partner (the National Heart, Lung, and Blood Institute at the National Institutes of Health). Comments from reviewers were presented to the USPSTF during its deliberation of the evidence and were considered in preparing the final evidence review.

Editorial Disclaimer: This evidence report is presented as a document in support of the accompanying USPSTF Recommendation Statement. It did not undergo additional peer review after submission to JAMA.

REFERENCES
19. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by

Conclusions
There was no direct evidence and limited indirect evidence on the benefits of PAD screening with the ABI in unselected or asymptomatic populations. Available studies suggest low sensitivity and lack of beneficial effect on health outcomes, but these studies have important limitations.


